title: Chylomicron-chylomicron remnant clearance by liver and bone marrow in rabbits. Factors that modify tissue-specific uptake.
abstract: The metabolism of [14C]cholesterol- and [3H]retinol-labeled chylomicrons obtained from canine thoracic duct or rabbit mesenteric lymph was investigated in normal fasted rabbits. Typically, 70-80% of the chylomicrons injected into the rabbits were cleared from the plasma in 20 min, and their uptake was accounted for principally by the liver and the bone marrow. Surprisingly, the bone marrow was a major site of uptake; the uptake ranged from about half that of the liver to a nearly equal amount. The importance and specificity of chylomicron-chylomicron remnant uptake by the bone marrow were established by demonstrating that (a) bone marrow throughout the body accumulated these lipoproteins, (b) the level of uptake was consistent regardless of how the values were calculated or how the chylomicrons were prepared, (c) the uptake represented specific binding, and (d) radiolabeled intestinal lipoproteins induced in vivo delivered cholesterol and retinol to the marrow. Electron microscopic examination of the rabbit bone marrow established that perisinusoidal macrophages uniquely accounted for the uptake of the chylomicrons. Whereas liver cleared a variety of both triglyceride-rich lipoproteins (chylomicrons, chylomicron remnants, and very low density lipoproteins) and cholesterol-rich lipoproteins (beta-very low density lipoproteins and high density lipoproteins containing apolipoprotein E), bone marrow uptake appeared to be restricted to the triglyceride-rich lipoproteins. More chylomicron remnants (generated in a hepatectomized rabbit) were cleared by the liver than by the bone marrow, and the addition of excess apolipoprotein E to chylomicrons resulted in their preferential uptake by the liver. The role of chylomicron-chylomicron remnant delivery of lipids or lipid-soluble vitamins to rabbit bone marrow is open to speculation, and whether triglyceride-rich lipoprotein uptake occurs to a significant extent in the bone marrow of humans remains to be determined.
authors.affiliation: Gladstone Foundation Laboratories for Cardiovascular Disease, University of California, San Francisco 94140-0608.
authors.forename: M M
authors.initials: MM
authors.lastname: Hussain
authors.forename: R W
authors.initials: RW
authors.lastname: Mahley
authors.forename: J K
authors.initials: JK
authors.lastname: Boyles
authors.forename: M
authors.initials: M
authors.lastname: Fainaru
authors.forename: W J
authors.initials: WJ
authors.lastname: Brecht
authors.forename: P A
authors.initials: PA
authors.lastname: Lindquist
mesh_terms: D000818:Animals; D001853:Bone Marrow / Q000378:metabolism* / Q000502:physiology / Q000648:ultrastructure; D002914:Chylomicrons / Q000493:pharmacokinetics* / Q000648:ultrastructure; D004285:Dogs; D008099:Liver / Q000378:metabolism* / Q000502:physiology / Q000648:ultrastructure; D008264:Macrophages / Q000378:metabolism / Q000648:ultrastructure; D008297:Male; D008657:Metabolic Clearance Rate; D009928:Organ Specificity; D011817:Rabbits; D013154:Spleen / Q000378:metabolism; D014280:Triglycerides / Q000493:pharmacokinetics
chemical_list: D002914:Chylomicrons; D014280:Triglycerides